Photrexa cross-linking kit 6ML
Ended Awarded Last action
- Contract number
- SPE2DR26FQWK5
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $30,675
Award facts
- Contract value 100% obligated
- $30,674.50 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $30,674.50 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Photrexa Cross-Linking Kit 6ml. The delivery order, issued January 12, 2026, with an ultimate completion date of February 3, 2026, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This award is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a contract valued at $499,999,999 that was awarded November 13, 2025, and extends through December 31, 2036.
The PPV-G GEN V program represents a $30.3 billion acquisition strategy designed to provide pharmaceutical and medical consumables to support Department of Defense healthcare operations globally. As a regional prime vendor contractor under this initiative, DMS Pharmaceutical Group has demonstrated substantial performance across a diverse product portfolio encompassing branded and generic prescription drugs, biologics, vaccines, specialty pharmaceuticals, and medical consumables. The Photrexa Cross-Linking Kit delivery order exemplifies the company's role in supplying specialized pharmaceutical products to military healthcare facilities, with DLA utilizing the flexible delivery order mechanism to procure recurring medical supply needs efficiently throughout the contract period.
Quick answers
Who was awarded contract SPE2DR26FQWK5?
SPE2DR26FQWK5 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 12, 2026.
How much is contract SPE2DR26FQWK5 worth?
The government has obligated $30,675 on SPE2DR26FQWK5.
Is contract SPE2DR26FQWK5 an order under another contract?
Yes. SPE2DR26FQWK5 is a delivery order under SPE2DR25D9353, an indefinite delivery contract.
Was contract SPE2DR26FQWK5 competed?
The extent of competition for SPE2DR26FQWK5 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award